• Rubicon Research discloses outcome of unannounced USFDA inspection at its Concord, Ontario R&D facility.
• The inspection, conducted from April 20-24, 2026, concluded without issuance of any Form-483 observations.
• Company affirms commitment to maintaining highest standards of compliance and quality in regulatory filing.